Elsevier

Pathology

Volume 45, Issue 3, April 2013, Pages 229-242
Pathology

Precursors and pathogenesis of ovarian carcinoma

https://doi.org/10.1097/PAT.0b013e32835f2264Get rights and content

Summary

The ultimate goal of defining cancer specific precursors is to facilitate early detection and intervention before the development of invasive malignancy. Unlike other malignancies involving the female genital tract such as cervical or endometrial carcinomas, precursor lesions of ovarian carcinomas have not been well characterised, resulting in a failure to develop effective screening programs. Recent clinicopathological and molecular studies have provided new insight into the origin and pathogenesis of ovarian carcinomas. It has been shown that ovarian cancer is comprised of different tumour types differing not only in morphology, but also in pathogenesis, molecular alterations and clinical progression. A dualistic model of ovarian carcinogenesis has been proposed. Type I tumours which include low grade serous, low grade endometrioid, clear cell, mucinous carcinomas and Brenner tumours, are generally indolent and tend to be genetically stable, although clear cell carcinoma would probably belong to an intermediate category. They demonstrate a step-wise progression from a benign precursor such as a benign to borderline tumour or endometriosis and are characterised by genetic aberrations targeting specific cell signalling pathways. Type II tumours comprise high grade serous, high grade endometrioid, and undifferentiated carcinomas as well as malignant mixed mesodermal tumours. They are clinically aggressive and exhibit high genetic instability with frequent p53 mutations. Mounting evidence suggests that many high grade serous carcinomas originate from the epithelium of the distal fallopian tube, and that serous tubal intraepithelial carcinoma (STIC) represents the putative precursor of these neoplasms. Low grade serous carcinomas arise via transformation of benign and borderline serous tumours, thought to be derived from inclusion cysts originating from the ovarian surface or tubal epithelium. Recently it has been suggested that papillary tubal hyperplasia may be a putative precursor lesion for serous borderline tumours. Both endometrioid and clear cell carcinomas develop from endometriosis, via alterations affecting different genetic pathways. The origin of mucinous and transitional cell neoplasms is not well characterised, although new data suggest a possible origin from transitional cell nests present at the tubal-mesothelial junction. Likewise, the pathogenesis of carcinosarcomas is also not well established because of their rarity but there is accumulating evidence that the carcinomatous component determines the course of the disease and gives rise to the malignant mesenchymal component. This review discusses recent developments in the pathogenesis of ovarian carcinoma, with particular emphasis on the putative precursor lesions that give rise to the major histological subtypes. Recognition of these lesions is not only important in improving the understanding of ovarian carcinogenesis, but it will also influence our approach to prevent, detect and treat these tumours.

References (186)

  • T. May et al.

    Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary

    Gynecol Oncol

    (2010)
  • L. Dubeau

    The cell of origin of ovarian epithelial tumours

    Lancet Oncol

    (2008)
  • M.M. Altaras et al.

    Primary paraovarian cystadeno-carcinoma: clinical and management aspects and literature review

    Gynecol Oncol

    (1990)
  • J. Li et al.

    Tubal origin of ‘ovarian’ low-grade serous carcinoma

    Mod Pathol

    (2011)
  • E. Oral et al.

    Prevalence of endometriosis in malignant epithelial ovary tumours

    Eur J Obstet Gynecol Reprod Biol

    (2003)
  • P. Russell

    The pathological assessment of ovarian neoplasms. I: Introduction to the common ‘epithelial’ tumours and analysis of benign ‘epithelial’ tumours

    Pathology

    (1979)
  • A. Horiuchi et al.

    Toward understanding the natural history of ovarian carcinoma development: a clinicopathological approach

    Gynecol Oncol

    (2003)
  • A. Finch et al.

    Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers

    Gynecol Oncol

    (2006)
  • J. Boyd

    Specific keynote: hereditary ovarian cancer: what we know

    Gynecol Oncol

    (2003)
  • H.A. Risch et al.

    Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer

    Am J Hum Genet

    (2001)
  • A.S. Sehdev et al.

    Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase

    Mod Pathol

    (2010)
  • V. Beral et al.

    Ovarian cancer and hormone replacement therapy in the Million Women Study

    Lancet

    (2007)
  • S. Salvador et al.

    Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma

    Gynecol Oncol

    (2008)
  • J. Carlson et al.

    Recent advances in the understanding of the pathogenesis of serous carcinoma: the concept of low-and high-grade disease and the role of the fallopian tube

    Diagn Histopathol

    (2008)
  • A. Saleemuddin et al.

    Risk factors for a serous cancer precursor (‘p53 signature’) in women with inherited BRCA mutations

    Gynecol Oncol

    (2008)
  • P.A. Shaw et al.

    Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers

    Mod Pathol

    (2009)
  • A.K. Folkins et al.

    A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations

    Gynecol Oncol

    (2008)
  • R. Sainz de la Cuesta et al.

    Histologic transformation of benign endometriosis to early epithelial ovarian cancer

    Gynecol Oncol

    (1996)
  • H. Jimbo et al.

    Prevalence of ovarian endometriosis in epithelial ovarian cancer

    Int J Gynaecol Obstet

    (1997)
  • S. Ogawa et al.

    Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study

    Gynecol Oncol

    (2000)
  • K. Kashima et al.

    Familial risk among Japanese patients with endometriosis

    Int J Gynaecol Obstet

    (2004)
  • A. Jemal et al.

    Global cancer statistics

    CA Cancer J Clin

    (2011)
  • D.A. Bell et al.

    Early de novo ovarian carcinoma. A study of fourteen cases

    Cancer

    (1994)
  • R.J. Kurman et al.

    Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications

    Int J Gynecol Pathol

    (2008)
  • K.R. Cho et al.

    Ovarian cancer

    Ann Rev Pathol

    (2009)
  • D. Maeda et al.

    Mucosal carcinoma of the fallopian tube coexists with ovarian cancer of serous subtype only: a study of Japanese cases

    Virchows Archiv

    (2010)
  • J.M. Piek et al.

    Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer

    J Pathol

    (2001)
  • C.G. Przybycin et al.

    Are all pelvic (nonuterine) serous carcinomas of tubal origin?

    Am J Surg Pathol

    (2010)
  • C.B. Gilks

    Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data

    Int J Gynecol Pathol

    (2004)
  • A. Malpica et al.

    Grading ovarian serous carcinoma using a two-tier system

    Am J Surg Pathol

    (2004)
  • N.L. Sieben et al.

    In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours

    J Pathol

    (2004)
  • G. Singer et al.

    Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor)

    Int J Gynecol Pathol

    (2003)
  • G. Singer et al.

    Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation

    Am J Surg Pathol

    (2005)
  • R.A. Soslow

    Histologic subtypes of ovarian carcinoma: an overview

    Int J Gynecol Pathol

    (2008)
  • R. Vang et al.

    Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems

    Adv Anat Pathol

    (2009)
  • R. Vang et al.

    Fallopian tube precursors of ovarian low- and high-grade serous neoplasms

    Histopathology

    (2013)
  • R.J. Kurman et al.

    The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory

    Am J Surg Pathol

    (2010)
  • W.G. McCluggage

    The pathology of and controversial aspects of ovarian borderline tumours

    Curr Opin Oncol

    (2010)
  • J.D. Seidman et al.

    Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases

    Am J Surg Pathol

    (1996)
  • C.J. Haas et al.

    In serous ovarian neoplasms the frequency of Ki-ras mutations correlates with their malignant potential

    Virchows Archiv

    (1999)
  • Cited by (115)

    • Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment

      2022, Seminars in Cancer Biology
      Citation Excerpt :

      One major distinctive feature is the disease stage at diagnosis, with LGSC cases usually detected at an early stage (FIGO stage I-II), in contrast to HGSC. The origin of LGSC is presumably a stepwise malignant transformation process, with lesions evolving from serous borderline tumors [43,44]. The rate of serous borderline tumors progressing into LGSC is around 5–10% [14,42,44].

    • Insight updating of the molecular hallmarks in ovarian carcinoma

      2020, European Journal of Cancer, Supplement
    View all citing articles on Scopus
    View full text